Evidence map›Paper›PMID 38363600›Full record

ArticleBreast disease2024

Clinicopathological analysis of 38 male patients diagnosed with breast cancer.

Seniha Irem Sahin, Serdar Balci, Gulnur Guler, Kadri Altundag

Open access · bronzeAbstract read
In one paragraph

Article in Breast disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Seniha Irem SahinDepartment of Pathology and Laboratory Medicine, Division of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Serdar BalciMemorial Hospital Group, Pathology Laboratory, Istanbul, Turkey.
Gulnur GulerBilen Pathology, Sakir Baki Sokak, Ankara, Turkey.
Kadri AltundagMKA Breast Cancer Clinic, Ankara, Turkey.
Istanbul Memorial Hospital · TRUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMale breast cancer (MBC) accounts for one percent of all breast cancers. Due to the lack of awareness and routine screening programs, most patients present with systemic disease at the time of diagnosis with low overall survival.

objectivesThis study aims to investigate the prognostic factors of male breast cancer and its correlation with established prognostic parameters and patient outcomes.

methodsThirty-eight male breast cancer patients are identified from the MKA Breast Cancer Clinic database, and their corresponding clinical and pathological characteristics are obtained. Cut-off values of 1% and 10% are applied to further classify ER and PR results.

resultsOlder men are more likely to develop MBC than younger men and are more likely to have spread to axillary lymph nodes. Invasive ductal carcinoma is a more common histologic type in MBC. All the tested patients have ER and PR positivity. Distant metastasis developed in 17/38 (44.7%) patients. Bone metastasis is seen commonly in metastatic MBC.

conclusionsAccording to our cohort, MBC is seen in older males, presents in later stages, and shows hormone receptor positivity and a tendency to bone involvement. MBC is a heterogenous but distinct biological entity requiring a specific clinical and pathological approach.

Indexed as

Bone NeoplasmsBreast NeoplasmsBreast Neoplasms, MaleCarcinoma, Ductal, BreastAgedHumansLymph NodesMalePrognosisReceptors, ProgesteroneReceptors, Progesteronebreast cancerMaleprognostic parameterssurvival

Identifiers

PMID38363600
PMCPMC10894578
OpenAlexW4391885091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.